In Reply We would like to thank Dr Bramati and colleagues for their comments regarding our randomized clinical trial.¹ They highlighted the critical need to translate the science demonstrating the benefits of specialty palliative care for patients with hematologic cancers into oncology practice. We agree wholeheartedly and want to emphasize the need for further dissemination and implementation research to ensure uptake, adoption, and sustainability of palliative care integration for patients with hematologic cancers across care settings. Dissemination and implementation research will also provide us with an opportunity to study the potential barriers and facilitators for integrating palliative care for patients with hematologic cancers in diverse, real-world clinical settings.